

Contribution to Societies

Contribution to global health Material issues

Development of drugs and vaccines to treat malaria, antimicrobial-resistant (AMR) bacterial infections, and influenza.

With global supply chain disruption caused by the spread of COVID-19 and the situation in Ukraine, the sustainability of healthcare internationally has become an urgent issue, and the expectations placed on pharmaceutical companies have increased even more.

We are committed to solving issues through research and development in the infectious diseases area that pose an international threat, such as malaria, AMR bacterial infections, and influenza. We believe that these efforts will not only contribute to the achievement of the SDGs and preparedness for future pandemics, but also enhance our presence as a global pharmaceutical company.

For malaria, we are continuing collaboration with Ehime University, the European Vaccine Initiative (EVI), and Instituto de Biología Experimental e Tecnológica (iBET) on a vaccine to prevent malaria disease, and with Ehime University and PATH in the United States on a vaccine to prevent malaria transmission and a vaccine to prevent infection. Each of these projects has been selected for funding by the Global Health Innovative Technology Fund (GHIT Fund).

For AMR bacterial infections, several Sumitomo Pharma researchers are sent to the drug discovery group (currently, the Satoshi Omura Memorial Institute) of Distinguished Emeritus Professor Satoshi Omura at The Kitasato Institute, and this joint team of Sumitomo Pharma and the Memorial Institute promoted research to create KSP-1007 (beta-lactamase inhibitor). In January 2022, we started a Phase 1 study of KSP-1007 in the United States. For influenza, preclinical research continues for a universal influenza vaccine in collaboration with the National Institutes of Biomedical Innovation, Health and Nutrition. The joint research for AMR and influenza has been selected as research and development projects related to the Japan Agency for Medical Research and Development's Cyclic Innovation for Clinical Empowerment project.

Strengthening of public-private collaboration on countermeasures against AMR and appropriate use of antibiotics

In 2019-2020, we partnered with 10 major hospitals in Vietnam to conduct drug susceptibility surveillance research aimed at the appropriate use of antibiotics and countermeasures to AMR. To help develop the capability of each medical institution to select the most appropriate

antibiotics for treatment, a detailed report and technical guidance for each hospital were completed in September 2020, and the study results were presented at the European Congress of Clinical Microbiology in July 2021 to be widely disseminated both in Vietnam and internationally. Preparations are underway for submission of papers for further clinical use, and in April 2022, we began preparations for the second round of drug susceptibility surveillance research (to be conducted in 2022-23).

Promotion of public awareness-raising activities for health, hygiene, and nutrition

Sumitomo Pharma provides an NPO-led health improvement program for mothers and children in Cambodia's Kampong Cham Province.

In fiscal 2021, the program made 591 home visits to pregnant women and 470 home visits to postpartum mothers, promoted health checks for pregnant women, postpartum mothers and infants, and raised awareness about nutrition and hygiene. In addition, cooking classes for making nutritious baby food were held 33 times, with a total of 691 local residents participating.

KPIs

- **Progress of development in infectious diseases area —Number of projects —Number of products (number of products launched)**

The number of projects and number of products (number of products launched) will be used as indicators to measure the progress of development and the Company's contribution in the infectious diseases area.

Fiscal 2021 progress: 6 projects, 0 products

- **Number of policy recommendations in infectious diseases area**

The number of policy recommendations will be set as an indicator to make further improvements in the environment in the infectious diseases area, which will promote research and development in the area.

Fiscal 2021 progress: 8 recommendations

- **Number of doctors and pharmacists who participated in the AMR countermeasure support program**

The number of participants in support programs to help healthcare professionals will be used as an indicator in efforts to further promote public awareness.

Fiscal 2021 progress: 31

- **Number of local residents assisted by maternal and child health programs in developing countries**

We will promote public awareness around health, hygiene, and nutrition by providing assistance to more local residents through our programs.

Fiscal 2021 progress: Cooking class participants: 691
Home visits: 1,061

Initiatives to improve access to medicines

Material issues

Even with today's advances in medicine, there are still many unmet medical needs, and an R&D-oriented pharmaceutical company has a mission to solve this issue. In addition, there are parts of the world where it is difficult for all people to receive equal access to necessary healthcare due to inadequate medical systems and poverty, disorder due to natural disasters and conflict, etc.

In addition to research and development of pharmaceuticals, Sumitomo Pharma works to solve issues related to healthcare access by raising public awareness of health, hygiene, and nutrition in collaboration with international organizations, government agencies, research institutions, and civil society. As part of these efforts, since 2017 Sumitomo Pharma has been participating in the Access Accelerated partnership initiative by organizations around the world, including global pharmaceutical companies, City Cancer Challenge, and PATH.

In fiscal 2021 we worked to raise public awareness regarding non-communicable diseases such as cancer, heart disease, and diabetes and strengthened medical exams during the COVID-19 pandemic, aiming for improvements in access to pharmaceuticals.

In response to the disruption of the supply of medicines in Eastern European countries due to the situation in Ukraine, we donated the antiepileptic drug Excegran Tablets to Ukraine and the Republic of Moldova on multiple occasions, for a total of 3.52 million tablets, and provided it to local residents and displaced persons in response to requests from the governments of Ukraine and neighboring countries.

Promotion of public awareness-raising activities with the aim of improving medicine-related literacy

Using pharmaceuticals with a proper appreciation and understanding of treatment methods and adverse reactions is very important in improving access to medicines. We provide "Kusuri-no-shiori," "Instructional Leaflets," and guidance for patients using our pharmaceuticals and their families to promote appropriate use.

Response to requests for the development of unapproved and off-label drugs

As an initiative to provide new treatment options in areas with high unmet medical needs, Sumitomo Pharma also addresses requests for development of unapproved and off-label drugs. Thus far, we have obtained four such approvals, including a conditioning treatment prior to

autologous hematopoietic stem cell transplantation for malignant lymphoma in March 2020. Also, in March 2022, we filed an application based on public knowledge of an additional indication for the biguanide oral hypoglycemic agent METGLUCO® Tablets for the treatment of infertility.

KPIs

- **Number of programs aiming to improve medicine-related literacy**

The number of programs implemented will be used as an indicator due to the importance of providing opportunities for people to correctly learn about treatment using medicines and their side effects.

Fiscal 2021 progress: 4 programs

- **Number of responses to requests for unapproved and off-label drugs**

The number of responses on unapproved and off-label drugs will be used as an indicator to measure our contribution to new treatment options.

Fiscal 2021 progress: 2 products

- **Number of policy recommendations by the Company on access to medicines**

We will also take part in policy recommendations aimed at provision of fairly-priced drugs, leading to regulatory development.

Fiscal 2021 progress: 11 recommendations

Improvement of healthcare infrastructure in developing countries

Material issues

Support for capacity building of healthcare professionals, development of healthcare networks, etc.

From July 2016, we have worked with NPOs, local governments, and the community to provide a health improvement program for mothers and children in Cambodia's Kampong Cham Province. To date, we have trained 62 Community Care volunteers for Mothers and Newborns, who visited the homes of 591 antenatal women and 470 postnatal women in fiscal 2021.

Moreover, in collaboration with the local government and health centers, and through these Community Care volunteers for Mothers and Newborns, we donated picture book-type texts on nutrition, health, and dentistry for mothers during home visits.



Home visit by a Community Care volunteers for Mothers and Newborns (Cambodia)

Contribution to Societies

KPIs

- **Number of community care volunteers trained through maternal and child health programs in developing countries**

- **Number of partnerships working to improve healthcare infrastructure in developing countries**

We will contribute to improving infrastructure in developing countries by setting the number of specialist human resources trained and the number of partnerships as indicators because securing human resources in healthcare and pharmaceutical deregulation are necessary to improve healthcare infrastructure in developing countries.

Fiscal 2021 progress: 62 people, 5 partnerships

Patient support and advocacy Material issues

Further improving disease-related literacy for patients, their families, and society

Holding public lectures

Sumitomo Pharma holds public lectures nationwide not only for patients and their families, but also for the wider general public with the objective of promoting the correct understanding of diseases and contributing to the solving social issues.

In fiscal 2021, we held 15 public lectures on Parkinson's disease dementia with Lewy bodies, 12 on the area of diabetes, and 1 on mental illness. These were held primarily online to prevent the spread of COVID-19.

From fiscal 2021, we have been conducting questionnaires on the level of understanding and satisfaction with the lectures, and have received positive evaluations from over 90% of respondents. We will continue conducting questionnaires and reflect the results in the lecture contents.

Working with patient advocacy groups (including donations)

In the spirit of our global slogan "Innovation today, healthier tomorrows," Sumitomo Pharma promotes patient advocacy activities in the hope that all patients and their families can lead healthier and more fulfilling lives.

Main donations in fiscal 2021

Patient advocacy

- Japan Patients Association
- Japan Fabry Disease Patients and Family Association
- Japan Epilepsy Association
- Japan Parkinson's Disease Association
- Dementia People and Family Association
- Children's Cancer Association of Japan
- Japan TSUBASA Association
- RDD JAPAN Organization

→ For details, please see the website.

Guidelines Concerning Transparency in Collaborations with Patient Groups
Fiscal 2021 Patient Group Collaboration Report (Only available in Japanese)

Advancing patient advocacy in the U.S.

Sunovion Pharmaceuticals Inc. participates in walks and bicycle rides throughout the year that raise awareness and funds supporting people living with serious mental illnesses and Parkinson's disease. National Alliance on Mental Illness (NAMI) Walks Your Way events occur across the United States to bring greater awareness to serious mental illness (SMI) and reduce stigmas associated with SMI. Participants gain a greater sense of community while raising funds to help people living in SMI. Sunovion participated in The American Parkinson Disease Association (APDA) Optimism Walk, and The Parkinson's Foundation's Moving Day as well.



Sunovion employees participating in walking events

Raising disease awareness and providing information through websites and SNS

We work with patient groups to create and publish websites aimed at providing information for patients and their families and raising disease awareness among the general public. In fiscal 2020, we also set up official accounts on YouTube and Facebook to diversify and enhance our channels for dissemination of information.

The purpose of "Kokoro Share" (→ [for details, please see the website, only available in Japanese](#)) content is contributing to better treatment and lifestyle by providing accurate and easy-to-understand information on schizophrenia and bipolar disorder for patients and their families.

The content of "Rehabili Kitchen for Parkinson's Disease Patients" (→ [for details please see the website, only available in Japanese](#)) on our Parkinson's Disease Station features cooking-themed rehabilitation that can be done at home. The concept of the video is that cooking with awareness of each individual movement leads to rehabilitation.

"Diabetes My Care Notebook" provides information on daily self-care through diet and exercise for those diagnosed with type 2 diabetes, which they can start straightaway. The contents range from easy-to-implement to those that require a little more preparation, and are easy to continue and fit into your lifestyle.



→ [For details, please see the website.](#)

Diabetes My Care Notebook (Only available in Japanese)

KPIs

• Activities from patient perspective through healthcare professionals

We will further promote activities from the patient perspective in the provision of information to healthcare professionals by MRs, in addition to our social contribution activities.

Fiscal 2021 progress:

Diabetes

- Held training on bringing attention to stigmatizing language (all Branch Senior Directors and Sales Office Directors)
- Distributed material for patients made by the Japan Association for Diabetes Education and Care

Psychiatry Area

- Promoted schizophrenia patient awareness through the use of materials
- Promoted employment support for schizophrenia patients and increased disease awareness and diagnosis rate of bipolar disorder through the use of disease awareness website, "Kokoro Share," -related materials

Neurology Area

- Promoted disease awareness on Parkinson's disease and on dementia with Lewy bodies by providing information using VR content (daily life experiences for patients and caregivers)
- Provided Parkinson's disease patient education materials: rehabilitation logbooks, "Rehabili Kitchen," etc.

• Level of understanding and satisfaction of participants in public lectures

The level of understanding and satisfaction of participants will be used as an indicator to measure how much we are contributing to raising awareness of diseases and solving social issues in the opportunities we have for contact with patients and the general public.

Fiscal 2021 progress: Understanding: 94.2%
Satisfaction: 90.7%

• Number of support activities through donations and cooperation with patients' associations

We will support the activities of patient groups to further increase literacy about diseases.

Fiscal 2021 progress: Donated to 9 organizations
Supported 1 organization's activity

• Dissemination to raise awareness of diseases through our website

The volume of contents that strengthens the raising of awareness about diseases and the provision of information will be used as an indicator as the dissemination of better information to patients and the general public is important for further increasing literacy.

Fiscal 2021 progress: New contents: 23

Contribution to Societies

Local community contribution Material issues


Fulfilling responsibilities and contributing as a member of the community with awareness of harmony with society

Providing learning opportunities leveraging our strengths as a pharmaceutical company

Since fiscal 2012, we have been providing visiting lectures at junior high and high schools. As medical technology continues to progress, we believe that bioethics is important in junior high and high school education as a discipline that does not offer simple right or wrong answers. Using an original program on bioethics and incorporating the particular perspective that a biology-related corporation can offer, Sumitomo Pharma employees deliver visiting lectures.

As a program that fosters young learners' abilities to think, feel, and empathize, the program has been highly praised by the Ministry of Economy, Trade and Industry and by classroom teachers.

In fiscal 2021, we use a class program we created on the topic of genome analysis and heredity, and held classes at 7 schools, and 551 students participated. Through this program, we hope that students will recognize the various and diverse ideas of other people, and their understanding of themselves and others will deepen. From fiscal 2021, we have not only conducted the lectures, but have also been conducting questionnaires on the level of understanding and satisfaction with the lectures, and have received positive evaluations from over 90% of respondents. We will continue conducting questionnaires to help us improve the program.



Our unique class program on genome analysis and genetics for high school students

We have continued participating in the "SDGs Quest Mirai Koshien"*1 in the Kansai Area Tournament since the first event (fiscal 2019) as a special sponsor based on our desire to support new ideas of high school students for solving social issues.

We believe that these initiatives will not only stimulate children's interest and involvement in science and improve the quality of education in local communities, but will also increase trust in the Company.

*1 SDGs Quest Mirai Koshien: a future-oriented contest in which high school students present SDGs Action ideas that are solutions for a variety of global and social problems, including climate change, energy, biodiversity, gender, water, and more.



The theme "Let's eliminate prejudice against mental health and go for consultation" devised by Hyogo Prefectural Hyogo Senior High School was selected for the Sumitomo Dainippon Pharma*2 Award.

*2 The Company's name in March 2022

Publishing the SUKOYAKA Compass website

Since fiscal 2012, Sumitomo Pharma has published "SUKOYAKA Compass" as a part of our website aimed at the children who will be forging the future and their families.

Through SUKOYAKA Compass, there is substantial content concerning medicine, from a description of research and development of the cutting-edge medicines using iPS cells to the specific work of pharmaceutical companies, how to use medicines, how to do free research on medicines, and, as the latest topic, an explanation of vaccines for the COVID-19 virus.

To make it more approachable for children, the magazine features an illustrator popular with teenagers and a navigator, "Scoppi," who explains and answers questions about medicines.

We hope that SUKOYAKA Compass will help children develop an interest in medicines and help them learn the importance of understanding and using medicines correctly.



→ For details, please see the website.
SUKOYAKA Compass (Only available in Japanese)

Social contributions and donations

We donate to organizations that are committed to support for patients and their families, global health, and contributing to the community, which are all important for us. In fiscal 2021, we made donations to 28 organizations from directors and employees, including 4 organizations that received matching donations from the company. We also participated in READYFOR (crowd funding) for COVID-19.

→ For details, please see the website.
Donations and Support

Cooperating in vaccination support work by pharmacist volunteers

The Osaka Pharmaceutical Association provided assistance to the Osaka City large-scale immunization center in providing vaccinations against COVID-19. Employees who agreed to cooperate and have pharmacist qualifications were recruited, and these employees used the volunteer leave system to assist with the vaccinations.

Contributing to the building of even stronger communities in North America

Since 2012, Sunovion's "Hands On!" community service program has engaged employees in volunteer activities that contribute to building even stronger communities in the areas where they live and work. So far, employees have volunteered more than 32,600 total hours to projects supporting youth and educational programs, health and medical services and community relief initiatives.

From 2020 to 2022, the program allowed not only employees to participate, but also their families, provided that measures were taken to prevent the transmission of COVID-19. Examples of activities included employees and

their families donating food, clothing, books and other items to a local support facility near their homes, sending appreciation letters to military personnel, and responding to online inquiries from university students regarding employment and other issues.



Volunteer activities

KPIs

• **Number of activities to support the development of the next generation and level of understanding and satisfaction of participants**

The level of understanding and satisfaction of participants (students and teachers) will be used as an indicator to measure the contribution of visiting lectures on the topics of bioethics and genome analysis.

Fiscal 2021 progress: Schools visited: 7
Participating Students: 551
Lecturers from the Company: 13
Understanding: 95.3%
Satisfaction: 98.1%

• **Number of donations for social contribution that lead to resolution of social issues (disasters, people with disabilities, the environment, biodiversity, etc.)**

We will contribute to solving social issues by supporting organizations involved in global health and education of the next generation, areas the Company places importance on.

Fiscal 2021 progress: 19

• **Number of charitable activities in local communities**

The level of implementation of employee participation-based activities and the number of participants will be used as indicators as it is important for employees to participate and to expand the circle of support.

Fiscal 2021 progress: 2